Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TET2 |
Variant | del |
Impact List | deletion |
Protein Effect | loss of function |
Gene Variant Descriptions | TET2 del indicates a deletion of the TET2 gene. |
Associated Drug Resistance | |
Category Variants Paths |
TET2 mutant TET2 inact mut TET2 del |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TET2 del | acute myeloid leukemia | sensitive | Selinexor | Preclinical - Cell culture | Actionable | In a preclinical study, Xpovio (selinexor) induced apoptosis in TET2-knockout acute myeloid leukemia cell lines, resulting in decreased cell viability in culture (PMID: 36746437). | 36746437 |
TET2 del | acute myeloid leukemia | sensitive | Eltanexor | Preclinical - Cell culture | Actionable | In a preclinical study, Eltanexor (KPT-8602) induced apoptosis in TET2-knockout acute myeloid leukemia cell lines, resulting in decreased cell viability in culture (PMID: 36746437). | 36746437 |
TET2 del | acute myeloid leukemia | sensitive | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, Lynparza (olaparib) inhibited colony formation of mouse acute myeloid leukemia cells harboring TET2 deletion along with a FLT3-ITD mutation in culture (PMID: 34215619). | 34215619 |